Zobrazeno 1 - 10
of 41
pro vyhledávání: '"adebrelimab"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Adebrelimab is a humanized monoclonal antibody against programmed death-ligand 1 (PD-L1) and is also a novel immune checkpoint inhibitor, which has been used in the first-line treatment of extensive stage small cell lung cancer (SCLC) with its unique
Externí odkaz:
https://doaj.org/article/1a33567ae4f94ab8a3644852ad461e45
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Immune checkpoint inhibitors (ICIs) combined with chemotherapy have improved overall survival in patients with small-cell lung cancer, but have also led to an increase in adverse effects. The incidence of ICI-induced paraneoplastic neurological syndr
Externí odkaz:
https://doaj.org/article/9a219cf9710a4f61aa03cdac15b23919
Autor:
Dawei Chen, Bing Zou, Butuo Li, Aiqin Gao, Wei Huang, Qian Shao, Xiangjiao Meng, Pinliang Zhang, Xiaoyong Tang, Xudong Hu, Yan Zhang, Jun Guo, Changhong Zhao, Jiajia Yuan, Qian Li, Changbin Zhu, Jinming Yu, Linlin Wang
Publikováno v:
EClinicalMedicine, Vol 75, Iss , Pp 102795- (2024)
Summary: Background: This phase II prospective trial aimed to investigate the efficacy and safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by sequential thoracic radiotherapy (TRT) combined with adebrelimab in extensive-s
Externí odkaz:
https://doaj.org/article/ed0b645bf07d4a3a8629b1e6c2966f9c
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveTo determine the cost-effectiveness of imported immune checkpoint inhibitors (ICIs) such as atezolizumab and durvalumab, and domestic ICIs like serplulimab and adebrelimab, in combination with chemotherapy for extensive-stage small cell lung
Externí odkaz:
https://doaj.org/article/27b729f3859d4633a2b39201519ce840
Publikováno v:
Risk Management and Healthcare Policy, Vol Volume 16, Pp 2521-2529 (2023)
Dongchu Zhou,1 Xinrui Dong,1 Zhen Zhou,2 Qiao Liu1 1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of China; 2School of Public Health and Preventive Medicine, Monash University, Melbourn
Externí odkaz:
https://doaj.org/article/c01585a78e67476990bba6eb85d2623f
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Tracheal small cell carcinoma (SCC) is a rare malignancy, for which the optimal treatment strategy has yet to be determined. Currently, treatment largely aligns with the therapeutic guidelines established for small cell lung cancer, although numerous
Externí odkaz:
https://doaj.org/article/e7eff81ca3b142959a36a9f96184f468
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Purpose: The aim of this study was to evaluate the cost-effectiveness of a recently approved first-line therapy (adebrelimab plus chemotherapy vs. chemotherapy alone) for patients with extensive-stage small-cell lung cancer (ES-SCLC) in the US and Ch
Externí odkaz:
https://doaj.org/article/b93152ab30ae4b6b93b08a550fd05707
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The findings of the CAPSTONE-1 trial showed that adebrelimab in combination with chemotherapy (etoposide-carboplatin) (ADCHM) is clinically beneficial as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-
Externí odkaz:
https://doaj.org/article/600ff39857e14be9a390e8ff74e42c09
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.